Posted On: 12/22/2016 12:19:08 PM
Post# of 76

$PTLF “Excitement in the company continues to grow as we await the pre-INAD study results for our dosing and preliminary toxicology of Vitalzul™ later this month. FDA/CVM submission of Vitalzul™ with the expert help of InnoVision Therapeutics will follow the pre-INAD studies” stated Dr. Salvagno, CEO of PetLife.
http://www.otcmarkets.com/stock/PTLF/news/Pet...34&b=y
http://www.otcmarkets.com/stock/PTLF/news/Pet...34&b=y

